Timothy M. Kuzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Timothy M. Kuzel has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Francine Foss
Authors' Affiliations: 1Department of Dermatology, 2Department of Medicine, Division of Hematology/Oncology, and 3Department of Preventive Medicine, and 4Robert H. Lurie Comprehensive Cancer Center, Northwestern University; 5Department of Medicine, University of Chicago, Chicago, Illinois; 6AGI Dermatics, Freeport, New York; and 7Department of Medicine, New England Medical Center, Boston, Massachusetts
2 shared publicationsJ Guitart
2 shared publicationsSteven T. Rosen
Authors' Affiliations: 1Department of Dermatology, 2Department of Medicine, Division of Hematology/Oncology, and 3Department of Preventive Medicine, and 4Robert H. Lurie Comprehensive Cancer Center, Northwestern University; 5Department of Medicine, University of Chicago, Chicago, Illinois; 6AGI Dermatics, Freeport, New York; and 7Department of Medicine, New England Medical Center, Boston, Massachusetts
2 shared publicationsA Rook
1 shared publicationAlfred Rademaker
Authors' Affiliations: 1Department of Dermatology, 2Department of Medicine, Division of Hematology/Oncology, and 3Department of Preventive Medicine, and 4Robert H. Lurie Comprehensive Cancer Center, Northwestern University; 5Department of Medicine, University of Chicago, Chicago, Illinois; 6AGI Dermatics, Freeport, New York; and 7Department of Medicine, New England Medical Center, Boston, Massachusetts
1 shared publicationAlfred W. Rademaker
Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University
1 shared publication
Latest Publications
- Open Access
- 17 October 2014
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 4 (4) , 448-458
A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
Background: Temozolomide is efficacious as an oral alternative for patients with metastatic melanoma (MM). Calcitriol has anti-proliferative properties and vitamin D receptor (VDR) polymorphisms are associated with alterations in melanoma susceptibility and progression. Methods: Tem 150 mg/m2 was administered on days 2–8 and 16–22 every 28 days. Calcitriol was given on days 1 and 15 every 28 days. VDR gene analysis was completed using PCR-RFLP based assays. Tolerability was the primary objective with secondary objectives of time to progression (TTP) and overall survival (OS). Results: Twenty pts with MM were registered. Cytopenias and thrombosis were the most common grade 3 or 4 toxicities. Median TTP was 1.8 mo. Pts with high-risk VDR genotype tt+/−ff (n = 6) had an OS of 3.8 mo from time of enrollment, compared to 7.4 mo for those with non-tt/ff genotypes (n = 11), although not statistically significant (HR = 1.20, 95% CI 0.41–3.53, p = 0.74). Conclusions: The extended dosing of Tem with calcitriol is a well-tolerated regimen. The trend toward improved OS in non-tt/ff VDR genotypes is consistent with prior studies associating the tt/ff genotype with biologic aggressiveness.
- 17 October 2014
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 4 (4) , 448-458
Open AccessA Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
Background: Temozolomide is efficacious as an oral alternative for patients with metastatic melanoma (MM). Calcitriol has anti-proliferative properties and vitamin D receptor (VDR) polymorphisms are associated with alterations in melanoma susceptibility and progression. Methods: Tem 150 mg/m2 was administered on days 2–8 and 16–22 every 28 days. Calcitriol was given on days 1 and 15 every 28 days. VDR gene analysis was completed using PCR-RFLP based assays. Tolerability was the primary objective with secondary objectives of time to progression (TTP) and overall survival (OS). Results: Twenty pts with MM were registered. Cytopenias and thrombosis were the most common grade 3 or 4 toxicities. Median TTP was 1.8 mo. Pts with high-risk VDR genotype tt+/−ff (n = 6) had an OS of 3.8 mo from time of enrollment, compared to 7.4 mo for those with non-tt/ff genotypes (n = 11), although not statistically significant (HR = 1.20, 95% CI 0.41–3.53, p = 0.74). Conclusions: The extended dosing of Tem with calcitriol is a well-tolerated regimen. The trend toward improved OS in non-tt/ff VDR genotypes is consistent with prior studies associating the tt/ff genotype with biologic aggressiveness.
- 20 March 2013
- Published by Springer Nature
- p. 135-140
Chemotherapy (Primary and Recurrent Disease)
- 7 February 2012
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 13 (1) , 102-121
Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments
- 7 February 2012
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 13 (1) , 102-121
Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (2) , S633-S634
Outcome of Patients Treated with a Single-Fraction Dose of Radiation for Cutaneous T-cell Lymphoma and Mycosis Fungoides
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (2) , S633-S634
Outcome of Patients Treated with a Single-Fraction Dose of Radiation for Cutaneous T-cell Lymphoma and Mycosis Fungoides
- 1 September 2011
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (17) , 5748-5754
Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Purpose: Temozolomide (TMZ) is an oral derivative of dacarbazine that induces DNA damage by methylating nucleotide bases. Resistance has been associated with high levels of O6-methylguanine-DNA methyltransferase (MGMT). Malignant CD4+ T cells of patients with mycosis fungoides/Sézary syndrome (MF/SS) have been shown to have low levels of MGMT and may be particularly sensitive to this methylator. Experimental Design: The efficacy of TMZ was evaluated in a multicenter phase II trial of patients with advanced stages of MF/SS. TMZ was given orally at daily doses of 200 mg/m2 for 5 days every 28 days. MGMT and mismatch repair protein expression was assessed by quantitative immunofluorescence and immunohistochemistry in skin and blood samples. Results: Twenty-six patients (stages IB–IVB) were evaluable for response. Patients had a median of four prior treatments. Median follow-up time was 19 months (range, 1–95). The overall response was 27% with two complete remissions (8%) and five partial remissions (19%). Median disease-free survival was 4 months. The median overall survival was 24 months. The most frequent toxicities included constitutional symptoms, gastrointestinal symptoms, and hematologic toxicities. Treatment was discontinued in three patients following grade 3 thrombocytopenia, lymphopenia, and skin reaction. The relationship between pretreatment MGMT and mutL homolog 1 (MLH1)/mutS homolog 2 (MSH2) mismatch repair protein expression levels in skin biopsies of cutaneous lesions and clinical response to TMZ were evaluated. Conclusions: Pretreatment levels of MGMT and MLH1/MSH2 protein levels are not predictive of response to TMZ in MF/SS, suggesting that other resistance mechanisms are important. Clin Cancer Res; 17(17); 5748–54. ©2011 AACR.
- 1 September 2011
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (17) , 5748-5754
Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Purpose: Temozolomide (TMZ) is an oral derivative of dacarbazine that induces DNA damage by methylating nucleotide bases. Resistance has been associated with high levels of O6-methylguanine-DNA methyltransferase (MGMT). Malignant CD4+ T cells of patients with mycosis fungoides/Sézary syndrome (MF/SS) have been shown to have low levels of MGMT and may be particularly sensitive to this methylator. Experimental Design: The efficacy of TMZ was evaluated in a multicenter phase II trial of patients with advanced stages of MF/SS. TMZ was given orally at daily doses of 200 mg/m2 for 5 days every 28 days. MGMT and mismatch repair protein expression was assessed by quantitative immunofluorescence and immunohistochemistry in skin and blood samples. Results: Twenty-six patients (stages IB–IVB) were evaluable for response. Patients had a median of four prior treatments. Median follow-up time was 19 months (range, 1–95). The overall response was 27% with two complete remissions (8%) and five partial remissions (19%). Median disease-free survival was 4 months. The median overall survival was 24 months. The most frequent toxicities included constitutional symptoms, gastrointestinal symptoms, and hematologic toxicities. Treatment was discontinued in three patients following grade 3 thrombocytopenia, lymphopenia, and skin reaction. The relationship between pretreatment MGMT and mutL homolog 1 (MLH1)/mutS homolog 2 (MSH2) mismatch repair protein expression levels in skin biopsies of cutaneous lesions and clinical response to TMZ were evaluated. Conclusions: Pretreatment levels of MGMT and MLH1/MSH2 protein levels are not predictive of response to TMZ in MF/SS, suggesting that other resistance mechanisms are important. Clin Cancer Res; 17(17); 5748–54. ©2011 AACR.
- 1 February 2008
- Vol. 143 (1) , 55-8
Interleukins in the treatment of mycosis fungoides.
Mycosis fungoides is typified by a cutaneous infiltrate of CD4+ lymphocytes with a Th2 phenotype. As the disease advances, there is increased expression of Th2 cytokines. This results in a subsequent suppression of Th1 cytokines and impaired cell mediated cytotoxic host response to the lymphoma cells. Disarming this cell mediate cytotoxic immune response creates a relentless cycle of disease progression. A cell mediated cytotoxic immune response can be stimulated with the use of Th1 cytokines such as IL-2 and IL-12. In this report, the Authors review the rational for the use of these particular cytokines in the treatment of mycosis fungoides. Further they comment on the experience and success regarding these two agents in phase I and II trials for the treatment of mycosis fungoides. Lastly, they discuss other potential cytokine therapies which could play a role in the future treatment of mycosis fungoides.
- 1 February 2008
- Vol. 143 (1) , 55-8
Interleukins in the treatment of mycosis fungoides.
Mycosis fungoides is typified by a cutaneous infiltrate of CD4+ lymphocytes with a Th2 phenotype. As the disease advances, there is increased expression of Th2 cytokines. This results in a subsequent suppression of Th1 cytokines and impaired cell mediated cytotoxic host response to the lymphoma cells. Disarming this cell mediate cytotoxic immune response creates a relentless cycle of disease progression. A cell mediated cytotoxic immune response can be stimulated with the use of Th1 cytokines such as IL-2 and IL-12. In this report, the Authors review the rational for the use of these particular cytokines in the treatment of mycosis fungoides. Further they comment on the experience and success regarding these two agents in phase I and II trials for the treatment of mycosis fungoides. Lastly, they discuss other potential cytokine therapies which could play a role in the future treatment of mycosis fungoides.
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (12) , 2397-2402
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497
Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing ≥20% IL-2R (IL-2R+) or <20% IL-2R (IL-2R−). DD was dosed at 18 µg/kg/day for 5 days every 21 days. Corticosteroid pre-medication was not allowed. Thirty-five patients of a planned 77 accrued due to closure for slow accrual. This report is on 29 patients (18 males) with indolent B-cell NHL (11 IL-2R+ and 18 IL-2R−). Histologic subtypes included small lymphocytic (SLL) (8 patients) and follicular grade I/II lymphoma (21 patients). Patients received a median of three prior regimens, including rituximab in 76%. Three partial responses were observed (RR 10%). The RR for the IL-2R− and IL-2R+ patients was 11% and 9%, respectively. Of 8 patients with SLL, 2 responded. Toxicities were generally grade I – II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy.
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (12) , 2397-2402
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497
Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing ≥20% IL-2R (IL-2R+) or <20% IL-2R (IL-2R−). DD was dosed at 18 µg/kg/day for 5 days every 21 days. Corticosteroid pre-medication was not allowed. Thirty-five patients of a planned 77 accrued due to closure for slow accrual. This report is on 29 patients (18 males) with indolent B-cell NHL (11 IL-2R+ and 18 IL-2R−). Histologic subtypes included small lymphocytic (SLL) (8 patients) and follicular grade I/II lymphoma (21 patients). Patients received a median of three prior regimens, including rituximab in 76%. Three partial responses were observed (RR 10%). The RR for the IL-2R− and IL-2R+ patients was 11% and 9%, respectively. Of 8 patients with SLL, 2 responded. Toxicities were generally grade I – II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6684
Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report
6684 Background: Denileukin diftitox (DD), a recombinant fusion protein of diphtheria toxin linked to interleukin-2, is FDA approved for the tx of cutaneous T-cell NHL. Initial studies of DD included several heavily pretreated pts with B-cell NHL, and objective responses were observed. This phase II trial was designed to evaluate the response rate (RR) and toxicity of DD in pts with relapsed low grade B-cell NHL, and to evaluate RR by tumor interleukin-2 receptor (IL-2R) expression. Methods: Eligible patients were stratified into two arms: pts with >20% IL-2R expression (IL-2R+) or patients with <20% IL-2R expression (IL-2R-) with independent response assessment for each group. DD was dosed at 18μg/kg/d for 5 days every 21 days for 2 cycles. Responders continued therapy for up to six cycles. Steroid premedication was not allowed. Results: The study closed prematurely due to slow accrual. Thirty of 35 pts entered were eligible and underwent treatment (18 M, 12 F; 12 IL-2R+ and 18 IL-2R-). The median pt age was 62. Twenty-eight pts (93%) had stage III or IV disease. Pts received a median of 3 prior regimens. Among the 29 pts with response information, the RR observed was 10% (90% CI: [3,25%]). There were no CRs and 3 PRs; 2 whose tumors were IL2R- (11% RR) and 1 whose tumor was IL-2R+ (8% RR). Ten pts maintained stable disease after tx, 10 pts had progressive disease and 6 pts were unevaluable. Eight pts had small lymphocytic NHL (SLL); 2 responded (25% RR; 90% CI: [5,60%]). At a median follow-up of 43 months, the median PFS was 4.1 months and the median OS was 46 months (18 months for IL-2R+ pts; not reached for IL-2R- pts). There was 1 case of lethal toxicity due to thromboembolism. Most toxicities were low grade and transient. Conclusions: DD is well tolerated and induces clinical responses in pts with previously treated low grade B-cell NHL. Responses were seen in IL-2R- tumors; SLL may represent a more sensitive NHL. Responses could not be attributed to corticosteroids as steroid premedication was prohibited. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ligand Ligand
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6684
Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report
6684 Background: Denileukin diftitox (DD), a recombinant fusion protein of diphtheria toxin linked to interleukin-2, is FDA approved for the tx of cutaneous T-cell NHL. Initial studies of DD included several heavily pretreated pts with B-cell NHL, and objective responses were observed. This phase II trial was designed to evaluate the response rate (RR) and toxicity of DD in pts with relapsed low grade B-cell NHL, and to evaluate RR by tumor interleukin-2 receptor (IL-2R) expression. Methods: Eligible patients were stratified into two arms: pts with >20% IL-2R expression (IL-2R+) or patients with <20% IL-2R expression (IL-2R-) with independent response assessment for each group. DD was dosed at 18μg/kg/d for 5 days every 21 days for 2 cycles. Responders continued therapy for up to six cycles. Steroid premedication was not allowed. Results: The study closed prematurely due to slow accrual. Thirty of 35 pts entered were eligible and underwent treatment (18 M, 12 F; 12 IL-2R+ and 18 IL-2R-). The median pt age was 62. Twenty-eight pts (93%) had stage III or IV disease. Pts received a median of 3 prior regimens. Among the 29 pts with response information, the RR observed was 10% (90% CI: [3,25%]). There were no CRs and 3 PRs; 2 whose tumors were IL2R- (11% RR) and 1 whose tumor was IL-2R+ (8% RR). Ten pts maintained stable disease after tx, 10 pts had progressive disease and 6 pts were unevaluable. Eight pts had small lymphocytic NHL (SLL); 2 responded (25% RR; 90% CI: [5,60%]). At a median follow-up of 43 months, the median PFS was 4.1 months and the median OS was 46 months (18 months for IL-2R+ pts; not reached for IL-2R- pts). There was 1 case of lethal toxicity due to thromboembolism. Most toxicities were low grade and transient. Conclusions: DD is well tolerated and induces clinical responses in pts with previously treated low grade B-cell NHL. Responses were seen in IL-2R- tumors; SLL may represent a more sensitive NHL. Responses could not be attributed to corticosteroids as steroid premedication was prohibited. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ligand Ligand
- 1 January 2005
- Published by Springer Nature in Medical Oncology
- Vol. 22 (4) , 399-406
Implications of Therapy Choice on Overall Survival in Metastatic Renal Cell Carcinoma: A Single Institution Experience
- 1 January 2005
- Published by Springer Nature in Medical Oncology
- Vol. 22 (4) , 399-406
Implications of Therapy Choice on Overall Survival in Metastatic Renal Cell Carcinoma: A Single Institution Experience
- 1 December 2003
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 16 (4) , 355-361
Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome
The treatment of mycosis fungoides and Sézary syndrome is unique. The treatments of choice are highly stage-and practitioner-dependent. For early stage patients, treatment with palliative topical therapies is often adequate to yield excellent, high-quality and durable responses. For the more advanced stages, systemic approaches are more appropriate, either alone or in combination, to palliate patients. There is still little convincing evidence from randomized trials that any single approach is favorable for improving survival. Many practitioners believe the disease can be controlled with the host immune system, but there again is little scientific support for this conclusion. It has been hypothesized that some of our therapies work through this mechanism, such as photopheresis and perhaps even psoralen and ultraviolet A. Unfortunately, even the use of biologic response modifiers, such as interferon and the interleukins, is not absolutely supportive of an active role for immune surveillance since these agents have been shown to have cytotoxic and differentiating effects. Because of the above, many practitioners have actively discouraged the use of chemotherapy because it may impair the host immune system; certainly, the purine analogs would fall into this category. However, there is little evidence supporting significant immune effects for other chemotherapeutics, and clearly, the responses seen would support their use in appropriate patients. As the present authors will detail in this paper, the advances in understanding cancer biology and mechanisms of resistance should, in the future, lead to optimal selection of agents that are predicted to be optimally active, limiting the toxicity and waste associated with ineffective drug usage.
- 1 December 2003
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 16 (4) , 355-361
Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome
The treatment of mycosis fungoides and Sézary syndrome is unique. The treatments of choice are highly stage-and practitioner-dependent. For early stage patients, treatment with palliative topical therapies is often adequate to yield excellent, high-quality and durable responses. For the more advanced stages, systemic approaches are more appropriate, either alone or in combination, to palliate patients. There is still little convincing evidence from randomized trials that any single approach is favorable for improving survival. Many practitioners believe the disease can be controlled with the host immune system, but there again is little scientific support for this conclusion. It has been hypothesized that some of our therapies work through this mechanism, such as photopheresis and perhaps even psoralen and ultraviolet A. Unfortunately, even the use of biologic response modifiers, such as interferon and the interleukins, is not absolutely supportive of an active role for immune surveillance since these agents have been shown to have cytotoxic and differentiating effects. Because of the above, many practitioners have actively discouraged the use of chemotherapy because it may impair the host immune system; certainly, the purine analogs would fall into this category. However, there is little evidence supporting significant immune effects for other chemotherapeutics, and clearly, the responses seen would support their use in appropriate patients. As the present authors will detail in this paper, the advances in understanding cancer biology and mechanisms of resistance should, in the future, lead to optimal selection of agents that are predicted to be optimally active, limiting the toxicity and waste associated with ineffective drug usage.